Comparison · NCT01945281-sae
Caspofungin vs Amphotericin B Deoxycholate: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Caspofungin vs Amphotericin B Deoxycholate: serious adverse events. Trial comparisons, record NCT01945281-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01945281-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.212 | 0.107 | 0.378 | wilson | |
| Risk in group 2 | 0.563 | 0.332 | 0.769 | wilson | |
| Risk difference, group 1 minus group 2 | -0.35 | -0.582 | -0.0665 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.377 | 0.172 | 0.828 | log | |
| Odds ratio, group 1 over group 2 | 0.209 | 0.0575 | 0.763 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Caspofungin than on Amphotericin B Deoxycholate | 2.85 | 1.72 | 15 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Caspofungin | Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment | 7 | 33 | EG000 |
| Group 2 | Amphotericin B Deoxycholate | Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment | 9 | 16 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 8 weeks after end of study therapy (up to 146 days)
Source ClinicalTrials.gov
Trial
- Title
- Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
- NCT number
- NCT01945281
- Phases
- PHASE2
- Conditions
- Candidiasis, Invasive
- Interventions
- Caspofungin, Amphotericin B Deoxycholate
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2018-08-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01945281?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01945281-sae